Last reviewed · How we verify

NCT03964571: CHEK BAC

Human and Bacterial Protease Activity As Prognostic Tool of Foot Infections in Diabetic Patients

Completed NA Last updated 18 December 2024
What this trial tests

NA trial testing WOUNDCHEK in Diabetic Foot Infection in 61 participants. Completed in 13 December 2024.

Timeline
9 October 2019
Primary endpoint
15 March 2024
13 December 2024

Quick facts

Lead sponsorCentre Hospitalier Universitaire de Nīmes
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment61
Start date9 October 2019
Primary completion15 March 2024
Estimated completion13 December 2024
Sites4 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire de Nīmes

Who can join

18 and older, any sex, with Diabetic Foot Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will establish whether human and bacterial protease activity can aid therapeutic decision-making, including targeted treatments.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetic Foot Infection

Currently open trials in the same condition.

Other Centre Hospitalier Universitaire de Nīmes trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03964571.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing